JP2024037776A5 - - Google Patents

Download PDF

Info

Publication number
JP2024037776A5
JP2024037776A5 JP2023203963A JP2023203963A JP2024037776A5 JP 2024037776 A5 JP2024037776 A5 JP 2024037776A5 JP 2023203963 A JP2023203963 A JP 2023203963A JP 2023203963 A JP2023203963 A JP 2023203963A JP 2024037776 A5 JP2024037776 A5 JP 2024037776A5
Authority
JP
Japan
Prior art keywords
ccr2
antibody
seq
attachment
point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023203963A
Other languages
English (en)
Japanese (ja)
Other versions
JP7799669B2 (ja
JP2024037776A (ja
Filing date
Publication date
Priority claimed from JP2022535215A external-priority patent/JP7397996B2/ja
Application filed filed Critical
Publication of JP2024037776A publication Critical patent/JP2024037776A/ja
Publication of JP2024037776A5 publication Critical patent/JP2024037776A5/ja
Priority to JP2025284233A priority Critical patent/JP2026076188A/ja
Application granted granted Critical
Publication of JP7799669B2 publication Critical patent/JP7799669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023203963A 2020-11-09 2023-12-01 抗体薬物コンジュゲート Active JP7799669B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025284233A JP2026076188A (ja) 2020-11-09 2025-12-26 抗体薬物コンジュゲート

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063111478P 2020-11-09 2020-11-09
US63/111,478 2020-11-09
US202163232935P 2021-08-13 2021-08-13
US63/232,935 2021-08-13
US202163250358P 2021-09-30 2021-09-30
US63/250,358 2021-09-30
JP2022535215A JP7397996B2 (ja) 2020-11-09 2021-11-09 抗体薬物コンジュゲート
PCT/IB2021/060356 WO2022097117A1 (en) 2020-11-09 2021-11-09 Antibody drug conjugates

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022535215A Division JP7397996B2 (ja) 2020-11-09 2021-11-09 抗体薬物コンジュゲート

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025284233A Division JP2026076188A (ja) 2020-11-09 2025-12-26 抗体薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2024037776A JP2024037776A (ja) 2024-03-19
JP2024037776A5 true JP2024037776A5 (cg-RX-API-DMAC7.html) 2024-11-18
JP7799669B2 JP7799669B2 (ja) 2026-01-15

Family

ID=78695752

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022535215A Active JP7397996B2 (ja) 2020-11-09 2021-11-09 抗体薬物コンジュゲート
JP2023203963A Active JP7799669B2 (ja) 2020-11-09 2023-12-01 抗体薬物コンジュゲート
JP2025284233A Pending JP2026076188A (ja) 2020-11-09 2025-12-26 抗体薬物コンジュゲート

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022535215A Active JP7397996B2 (ja) 2020-11-09 2021-11-09 抗体薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025284233A Pending JP2026076188A (ja) 2020-11-09 2025-12-26 抗体薬物コンジュゲート

Country Status (14)

Country Link
US (4) US20220168330A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240488B1 (cg-RX-API-DMAC7.html)
JP (3) JP7397996B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230106606A (cg-RX-API-DMAC7.html)
AU (1) AU2021374958A1 (cg-RX-API-DMAC7.html)
CA (1) CA3197167A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006136A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP23042551A (cg-RX-API-DMAC7.html)
IL (1) IL302390A (cg-RX-API-DMAC7.html)
MX (1) MX2023005381A (cg-RX-API-DMAC7.html)
PE (1) PE20231947A1 (cg-RX-API-DMAC7.html)
TW (1) TW202233251A (cg-RX-API-DMAC7.html)
WO (1) WO2022097117A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304464B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
PH12020550585A1 (en) 2017-11-10 2021-04-19 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
JP7397996B2 (ja) * 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
WO2024114605A1 (zh) * 2022-11-29 2024-06-06 杭州阿诺生物医药科技有限公司 一种融合多肽及其用途
LT4601703T (lt) 2023-04-18 2026-06-25 Astrazeneca Ab Konjugatai, apimantys atskeliamuosius jungtukus
TW202545568A (zh) 2024-01-29 2025-12-01 日商第一三共股份有限公司 抗her2抗體-藥物結合物與其他劑之組合
WO2026053158A1 (en) 2024-09-06 2026-03-12 Takeda Pharmaceutical Company Limited Dazostinag or conjugates thereof for treatment of neuroendocrine neoplasms
WO2026053159A1 (en) 2024-09-06 2026-03-12 Takeda Pharmaceutical Company Limited Dazostinag or conjugates thereof for treatment of adenoid cystic carcinomas

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
CA1213229A (en) 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
SE9600820D0 (sv) 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
AU2001233277B2 (en) 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
EP1645561A1 (en) 2003-07-15 2006-04-12 Mitsui Chemicals, Inc. Method of synthesizing cyclic bisdinucleoside
JP2007500697A (ja) 2003-07-28 2007-01-18 デイビッド・ケイ・アール・カラオリス 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US20090012038A1 (en) 2004-10-18 2009-01-08 Spormann Alfred M Methods for microbial biofilm destruction and interference with microbial cellular physiology
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
DE102006015341A1 (de) 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN102239180B (zh) 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
US20120178710A1 (en) 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
US9090646B2 (en) 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016506408A (ja) 2012-12-19 2016-03-03 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
WO2014109256A1 (ja) 2013-01-09 2014-07-17 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
EP3071229A4 (en) 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
EP3233191A1 (en) 2014-12-16 2017-10-25 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
DK3233882T3 (da) 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
WO2017011444A1 (en) 2015-07-13 2017-01-19 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating b cell cancers
TW201717968A (zh) 2015-07-14 2017-06-01 春季銀行製藥公司 誘導rig-i和其他模式辨識受體之化合物及組成物
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
US20170146519A1 (en) 2015-11-20 2017-05-25 Oregon Health & Science University Sting agonists and methods of selecting sting agonists
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
US20180369268A1 (en) 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SMT202500412T1 (it) 2016-01-11 2025-11-10 Innate Tumor Immunity Inc Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
US20190105282A1 (en) 2016-03-23 2019-04-11 Che-Ming Jack Hu Thin-shell polymeric nanoparticles and uses thereof
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018009652A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CA3029644A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
SG11201900154VA (en) 2016-07-15 2019-02-27 Sperovie Biosciences Inc Compounds, compositions, and methods for the treatment of disease
US20190345191A1 (en) 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
JP6636673B2 (ja) 2016-10-04 2020-01-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. STINGアゴニストとしてのベンゾ[b]チオフェン化合物
WO2018065360A1 (de) 2016-10-07 2018-04-12 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
WO2018100558A2 (en) * 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
JP2018090562A (ja) * 2016-12-01 2018-06-14 武田薬品工業株式会社 環状ジヌクレオチド
RU2019122598A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018118664A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
WO2018119117A1 (en) 2016-12-22 2018-06-28 The Regents Of The University Of California Methods of producing cyclic dinucleotides
ES2891326T3 (es) 2017-01-27 2022-01-27 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de la STING
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
ES2924186T3 (es) 2017-01-27 2022-10-05 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de STING
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
CA3053568A1 (en) 2017-02-21 2018-08-30 Board Of Regents, The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
CN106667914B (zh) 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
EP3612563A1 (en) * 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
TWI808092B (zh) 2017-08-30 2023-07-11 中國大陸商北京軒義醫藥科技有限公司 作為干擾素基因調節劑之刺激劑的環狀二核苷酸
EP3676277A1 (en) 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル-マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
US10738056B2 (en) 2017-09-15 2020-08-11 Aduro Biotech Inc. Pyrazolopyrimidinone compounds and uses thereof
PH12020550585A1 (en) 2017-11-10 2021-04-19 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
CA3092155A1 (en) * 2018-03-20 2019-09-26 Dana-Farber Cancer Institute, Inc. Compositions and methods for cancer treatment
EP3768685A1 (en) * 2018-03-23 2021-01-27 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
US12129402B2 (en) 2018-09-11 2024-10-29 Nippon Sheet Glass Company, Limited Liquid composition for optical filters and optical filter
TWI925817B (zh) * 2019-05-10 2026-05-21 日商武田藥品工業股份有限公司 抗體藥物結合物
JP2023072104A (ja) * 2020-04-10 2023-05-24 小野薬品工業株式会社 抗体薬物複合体
JP7397996B2 (ja) * 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート

Similar Documents

Publication Publication Date Title
US11104968B2 (en) Site-specific conjugation of linker drugs to antibodies and resulting ADCS
JP7402807B2 (ja) グリピカン3抗体およびそのコンジュゲート
CN106938051B (zh) 靶向于组织因子的抗体-药物偶联物
US9822183B2 (en) CA6 antigen-specific cytotoxic conjugate and methods of using the same
CN107469089B (zh) 一种peg连接子及配基药物偶联物
US20190290775A1 (en) Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor
WO2023036137A1 (en) Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies
KR20230015301A (ko) 2성분 독소가 부하된 항체-약물 접합체 및 그의 용도
CN107735093A (zh) Cd123抗体和其结合物
IL257839A (en) Doses of antibody and sn-38 immunocouplers for improved efficacy and reduced toxicity
CN105451775A (zh) 药物抗体缀合物
JP7455188B2 (ja) コンジュゲーションのためのポリペプチド複合体及びその応用
CN120826405A (zh) 具有靶向作用的偶联物及其制备方法和用途
JP7203834B2 (ja) イムノコンジュゲートにおけるメチオニン酸化を防止する方法
CN117157098A (zh) 一种药物组合及其用途
AU2005335743A1 (en) A CA6 antigen-specific cytotoxic conjugate and methods of using the same
CN117257977A (zh) 用于制备抗体药物偶联物的方法
CN117180449A (zh) 抗体药物偶联物的制备方法
CN108653746B (zh) 一种多载药点、高载药配基药物偶联物
JP2024540536A5 (cg-RX-API-DMAC7.html)
AU2012201260B2 (en) A CA6 antigen-specific cytotoxic conjugate and methods of using the same
CN120923577A (zh) 大环类药物偶联物及其制备方法和用途
CN120774988A (zh) 一种连接子、抗体药物偶联物及其制备方法